the benefit of autologous transplantation in the era of novel agents in multiple myeloma
Published 1 year ago • 136 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
1:48
the role of autologous transplantation in young and fit patients with multiple myeloma in 2022
-
3:44
is double autologous transplantation in multiple myeloma superior in the age of new agents?
-
2:39
the role of tandem transplantation in multiple myeloma & how this may be impacted by novel agents
-
3:06
the importance of autologous transplantation in the era of immunotherapy
-
4:17
the evolving role of autosct in the age of car-t for multiple myeloma: current & future perspectives
-
6:23
how long will i live with multiple myeloma and is there a cure?
-
19:39
t-cell engagers: targets, challenges and opportunity
-
4:04
the future of myeloma treatment and the possibility of cure
-
2:28
is autologous stem cell transplantation still the backbone of multiple myeloma treatment?
-
1:43
feasibility of double autologous stem cell transplantation in patients with al amyloidosis
-
3:10
the impact of gender on the outcomes of patients with myeloma undergoing autologous transplantation
-
3:47
using mrd to analyze the benefit of autologous sct in patients with myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
2:10
phase ii study of epd maintenance after second autologous transplant for multiple myeloma
-
2:49
the importance of timing in autologous transplantation for multiple myeloma
-
3:15
novel agents for consolidation after auto-sct in myeloma
-
1:22
the potential use of car-t therapy following autologous transplantation in multiple myeloma
-
1:30
exploring the role of upfront autosct in multiple myeloma
-
0:43
why should autologous transplant remain the soc in myeloma?
-
0:44
autologous transplantation in dlbcl and unmet needs
-
1:33
the role of allogeneic transplantation in patients with multiple myeloma